# ICMR Licenses SHetA2 for Early Cervical Cancer Trials 2026-08-07T09:51:27+00:00 | Health & Science | Indian Opinion Desk Corroboration: 1 independent outlet The Indian Council of Medical Research has licensed the experimental drug SHetA2 to Emcure Pharmaceuticals for manufacturing, regulatory development and human clinical trials. Developed through research at the University of Oklahoma and evaluated by ICMR’s National Institute of Cancer Prevention and Research, SHetA2 is designed to target HPV-infected cervical cells while preserving healthy tissue. The drug could eventually help treat high-grade precancerous lesions and early cervical cancer, reducing reliance on surgery that can affect future pregnancies. It remains unapproved for patient use. Trials must establish its safety, dosage, side effects and effectiveness against existing treatments. Researchers estimate development may take about five years. India records nearly 80,000 new cervical cancer cases and more than 42,000 deaths annually, according to the World Health Organization. ## Coverage - timesnownews.com Tags: cervical cancer, clinical trials, HPV, ICMR, SHetA2 Canonical: https://indianopinion.org/icmr-licenses-sheta2-for-early-cervical-cancer-trials/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/icmr-licenses-sheta2-for-early-cervical-cancer-trials/#story-in-brief Review state: restored archive article, accurate at time of publication, not offered to search indexes.